1. (Twice amended) An ApoA-I agonist compound comprising:

(i) a 15 to 29-residue peptide or peptide analogue which forms an amphipathic α-helix in the presence of lipids and which comprises formula (I) :

B1

Z_1 -X_1 - X_2 - X_3 - X_4 - X_5 - X_6 - X_7 - X_8 - X_9 - X_{10} - X_{11} - X_{12} - X_{13} - X_{14} - X_{15} - X_{16} - X_{17} - X_{18} - X_{19} - X_{20} - X_{21} - X_{22} -X_{23} -Z_2

or a pharmaceutically acceptable salt thereof, wherein:

X_1 is Pro (P), Ala (A), Gly (G), Gln (Q), Asn (N), Asp (D) or D-Pro (p);

X_2 is an aliphatic residue;

X_3 is a Leu (L) or Phe (F);

X_4 is Glu (E)

X_5 is an aliphatic residue;

X_6 is Leu (L) or Phe (F);

X_7 is Glu (E) or Leu (L);

X_8 is Asn (N) or Gln (Q);

X_9 is Leu (L);

X_{10} is Leu (L), Trp (W) or Gly (G);

X_{11} is an acidic residue;

X_{12} is Arg (R);

X_{13} is Leu (L) or Gly (G);

X_{14} is Leu (L), Phe (F) or Gly (G);

X_{15} is Asp (D);

X_{16} is Ala (A);

X_{17} is Leu (L);

X_{18} is Asn (N) or Gln (Q);

X_{19} is a basic residue;

X_{20} is a basic residue;

X_{21} is Leu (L);

X_{22} is a basic residue;

X_{23} is absent or a basic residue;

Z_1 is R_2N- or RC(O)NR-;

Z_2 is -C (O) NRR or -C (O) OR;

each R is independently -H, (C_1-C_6) alkyl, (C_1-C_6) alkenyl, (C_1-C_6) alkynyl, (C_5-C_{20}) aryl, (C_6-C_{26}) alkaryl, 5-20 membered heteroaryl or 6-26 membered alkheteroaryl or a 1 to 7-residue peptide or peptide analogue in which one more bonds between residues 1-7 are independently a substituted amide, an isostere of an amide or an amide mimetic;

B1 cont'd

each "-" between residues X_1 to X_{23} and between residues of the peptide to Z_2 independently designates an amide linkage, a substituted amide linkage, an isostere of an amide or an amide mimetic; or

(ii) a 15 to 26-residue deleted peptide or peptide analogue according to formula (I) in which one or two helical turns of the peptide or peptide analogue are optionally deleted.

Please add the following new claims:

Rule 1.126 56 ~~43.~~ (New) The 15 to 26-residue deleted peptide or peptide analogue of Claim 1, in which one helical turn is deleted.

57 ~~44.~~ (New) The 15 to 26-residue deleted peptide or peptide analogue of Claim 1, in which three, four, six, seven or eight residues X_1 , X_2 , X_3 , X_4 , X_5 , X_6 , X_7 , X_8 , X_9 , X_{10} , X_{11} , X_{12} , X_{13} , X_{14} , X_{15} , X_{16} , X_{17} , X_{18} , X_{19} , X_{20} , X_{21} and X_{22} are deleted.

58 ~~45.~~ (New) The 15 to 26-residue deleted peptide or peptide analogue of Claim 44, in which 3 consecutive residues are deleted.

B2

59 ~~46.~~ (New) The 15 to 26-residue deleted peptide or peptide analogue of Claim 44, in which 4 consecutive residues are deleted.

60 ~~47.~~ (New) The 15 to 26-residue deleted peptide or peptide analogue of Claim 44, in which two non-contiguous sets of 3 consecutive residues are deleted.

61 ~~48.~~ (New) The 15 to 26-residue deleted peptide or peptide analogue of Claim 44, in which two non-contiguous sets of 4 consecutive residues are deleted.

62 ~~49.~~ (New) The 15 to 26-residue deleted peptide or peptide analogue of Claim 44, in which one set of 3 consecutive residues and one set of 4 consecutive residues are deleted.

63 ~~50.~~ (New) The 15 to 26-residue deleted peptide or peptide analogue of Claim 44, in which 6, 7 or 8 consecutive residues are deleted.

64 ~~51.~~ (New) The 15 to 26-residue deleted peptide or peptide analogue of Claim 44, in which residues 18, 19, 20 and 22 are not deleted.

65 ~~52.~~ (New) The 15 to 26-residue deleted peptide or peptide analogue of Claim 1, in which residues 3, 6, 9 and 10 are not deleted.

66 ~~53.~~ (New) The 15 to 26-residue deleted peptide or peptide analogue of Claim 1, in which X_{23} is absent.

67 ~~54.~~ (New) The 15 to 26-residue deleted peptide or peptide analogue of Claim 1 in which:

the "-" between residues designates -C (O) NH- ;

Z_1 is H_2N- ; and

Z_2 is -C (O) OH or a salt thereof.

68 ~~55.~~ (New) The 15 to 26-residue deleted peptide or peptide analogue of Claim 1, in which the mean hydrophobic moment, $<\mu_H>$, is about 0.45 to about 0.65.

BZ Cont

69 ~~56.~~ (New) The 15 to 26-residue deleted peptide or peptide analogue of Claim 55, in which the mean hydrophobic moment, $<\mu_H>$, is about 0.50 to about 0.60.

70 ~~57.~~ (New) The 15 to 26-residue deleted peptide or peptide analogue of Claim 1, in which the mean hydrophobicity, $<H_o>$, is about -0.050 to about -0.070.

71 ~~58.~~ (New) The 15 to 26-residue deleted peptide or peptide analogue of Claim 1, in which the mean hydrophobicity, $<H_o>$, is about -0.030 to about -0.055.

72 ~~59.~~ (New) The 15 to 26-residue deleted peptide or peptide analogue of Claim 1, in which the mean hydrophobicity of the hydrophobic face, $<H_o^{pho}>$, is about 0.90 to about 1.20.

73 ~~60.~~ (New) The 15 to 26-residue deleted peptide or peptide analogue of Claim 59, in which the mean hydrophobicity of the hydrophobic face, $<H_o^{pho}>$, is about 0.94 to about 1.10.

74 ~~61.~~ (New) The 15 to 26-residue deleted peptide or peptide analogue of Claim 1, in which the pho angle is about 160° to about 220°.

75 ~~62.~~ (New) The 15 to 26-residue deleted peptide or peptide analogue of Claim 61, in which the pho angle is 180° to about 200°.

76 ~~63.~~ (New) An ApoA-I agonist-lipid complex comprising an ApoA-I agonist compound and a lipid, wherein the ApoA-I agonist compound is a deleted peptide or peptide analogue according to Claim 1.

77 ~~64.~~ (New) An ApoA-I agonist-lipid complex comprising an ApoA-I agonist compound and a lipid, wherein the ApoA-I agonist compound is a deleted peptide or peptide analogue according to Claim 43, 44, 50 or 51.

B2 cont 78 ~~65.~~ (New) The ApoA-I agonist-lipid complex of Claims 63 or 64, in which the lipid is sphingomyelin.

79 ~~66.~~ (New) A pharmaceutical composition comprising an ApoA-I agonist compound and a pharmaceutically acceptable carrier, excipient or diluent, wherein the ApoA-I agonist compound is a deleted peptide or peptide analogue according to Claim 1 or 44.

80 ~~67.~~ (New) The pharmaceutical composition of Claim 66, in which the ApoA-I agonist compound is in the form of an ApoA-I agonist compound-lipid complex, said complex comprising the deleted ApoA-I agonist compound and a lipid.

81 ~~68.~~ (New) The pharmaceutical composition of Claim 67 in which the lipid is sphingomyelin.

82 ~~69.~~ (New) The pharmaceutical composition of Claim 67 or 68 in which the ApoA-I agonist compound-lipid complex is in the form of a lyophilized powder.

83 ~~70.~~ (New) The pharmaceutical composition of Claim 67 or 68 in which the ApoA-I agonist compound-lipid complex is in the form of a solution.